Key result
Updated 2024 CAD review highlights shorter DAPT post-PCI, broadened occlusion ECG criteria, and new guidelines.
Why the study?
Multiple breakthroughs in coronary artery disease published across leading cardiology journals in 2024 warranted appraisal and clinical summarisation.
This 2024 update provides a comprehensive overview of practice-changing evidence in the assessment and management of coronary artery disease.
May guide CAD care updates; leaves open rigorous testing of new occlusion MI criteria.
2024 has been a remarkable year in the field of coronary artery disease. There have been key breakthroughs at every stage of a patient's journey, from investigation to medical treatment and intervention, and many new findings are already changing practice. In this review article, we appraise and summarise the most important new evidence published in 2024 from five of the highest impact factor cardiology journals. Topics discussed include acute myocardial infarction in the elderly, antiplatelet de-escalation after percutaneous coronary intervention, the role of beta-blockers after myocardial infarction and efficacy of the microaxial flow pump in cardiogenic shock, alongside many more. We refer to the new changes in the 2024 European Society of Cardiology Chronic Coronary Syndrome guidelines in parallel to provide the reader with a clinically relevant and up-to-date review of coronary artery disease.
No takes yet. Share an insight, caveat, or question.
A 2025 study conducted a review in Coronary artery disease. 2024 updates in coronary artery disease management was evaluated. The 2024 update highlights key breakthroughs in coronary artery disease, including abbreviated dual antiplatelet therapy after PCI, broadened ECG criteria for occlusion, and new ESC guidelines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: